Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture

Journal of Infectious Diseases

Volumn 200, Issue 6, 2009, Pages 841-848

  Szymczakiewicz Multanowska, Agnieszka ^a   Groth, Nicola ^b,e   Bugarini, Roberto ^b,f   Lattanzi, Maria ^b   Casula, Daniela ^b   Hilbert, Anne ^c   Tsai, Theodore ^d   Podda, Audino ^b  

^a Center for Clinical Pharmacology Research   (Poland)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Novartis Vaccines and Diagnostics   (Germany)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^e Genomic Health Inc ^*  (Italy)

^f Genomic Health Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EGG; ERYTHEMA; EUROPEAN UNION; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HEALTH STATUS; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INCIDENCE; INDUCED HYPOTHERMIA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; KIDNEY CELL; MAJOR CLINICAL STUDY; MALAISE; MALE; MAMMAL CELL; MULTICENTER STUDY; MYALGIA; PAIN; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN INDURATION; SWEATING; SWELLING; VACCINATION; VACCINE PRODUCTION; VIRUS STRAIN; ADOLESCENT; ANIMAL; BLOOD; CELL LINE; DOG; IMMUNOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DOGS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 70349301585     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605505     Document Type: Article

References (30)

1. World Health Organization (WHO). Influenza vaccines. Wkly Epidemiol Rec 2005;80:277-288
2. Fiore AE, Shay DK, Broder K. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57:1-60.
3. Roberston JS. Clinical influenza virus and the embryonated hen's egg. Rev Med Virol 1993;3:97-106.
4. 4. Widjaja L, Ilyushina N, Webster RG, Webby RJ. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 2006;350:137-145 (Pubitemid 43870192)
5. Harmon MW, Rota PA, Walls HH, Kendal AP. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 1988;26:333-337
6. 6. Lu B, Zhou H, Chan W, Kemble G, Jin H. Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine 2006; 24: 6691-6693 (Pubitemid 46107169)
7. Audsley JM, Tannock GA. The role of cell culture vaccines in the control of the next influenza pandemic. Expert Opin Biol Ther 2004; 4:709-717
8. Mabrouk T, Ellis RW Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). DevBiol (Basel) 2002;110:125-134
9. 9. Ito T, Suzuki Y, Takada A, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997; 71: 3357-3362 (Pubitemid 27121583)
10. Çinkaya I, Gregersen JP, Hilbert AK. Novel process for a MDCK suspension cell culture derived influenza subunit vaccine [poster]. Presented at the 11th International Congress on Infectious Diseases (Cancun, Mexico) 2004.
11. Palache AM, Scheepers HS, de Regt V, et al. Safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine: a meta-analysis of clinical studies. Dev Biol Stand 1999;98:115-25; discussion 133-134
12. 12. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001; 19:3444-3450 (Pubitemid 32710294)
13. 13. Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20:1240-1247 (Pubitemid 34135962)
14. Tobita K. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol 1975; 162:23-27
15. Trusheim H, Roth B, Wilms R. The MDCK 33016-PF cell-line is not only suitable for the production of cell-based influenza vaccine but is also an ideal substrate for influenza virus isolation [poster]. Presented at Options for the Control of Influenza VI (Toronto). 2007.
16. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential phase I and phase II clinical trial. Vaccine 2009;27:786-791
17. Recommended composition of influenza virus vaccines for use in the 2004-2005 influenza season. Wkly Epidemiol Rec 2004; 79:88-92.
18. 18. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-95 (Pubitemid 38649066)
19. Centers for Disease Control and Prevention. Assessment of the effectiveness of the 2003-2004 influenza vaccine among children and adults- Colorado, 2003. MMWR Morb Mortal Wkly Rep 2004;53:707-710
20. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:3094-3101 (Pubitemid 29366990)
21. 21. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003;21:4234-4237 (Pubitemid 37130269)
22. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-3143
23. 23. Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Longterm clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine 2006;24:1586-1592 (Pubitemid 43238234)
24. Reisinger KS, Block SL, Izu A, Groth N, Holmes S. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009;200:849-857 (in this issue).
25. 25. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960-968 (Pubitemid 28276008)
26. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 1999; 98:39-51; discussion 73-74
27. 27. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007;297:1577-1582 (Pubitemid 46588371)
28. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002; 110:834-840
29. Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine 1995; 13: 1583-1588
30. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990;64:1808-1811